Literature DB >> 10645841

Severe gamma-hydroxybutyrate withdrawal: a case report and literature review.

K Craig1, H F Gomez, J L McManus, T C Bania.   

Abstract

We report a case of gamma-hydroxybutyrate (GHB) withdrawal resulting in severe agitation, mental status changes, elevated blood pressure, and tachycardia hours after stopping chronic use of GHB. The patient admitted to substantial GHB abuse on a daily basis for 2.5 years. Previous attempts at cessation reportedly resulted in diaphoresis, tremors, and agitation. The patient's symptoms, negative polypharmacy history, and negative urine and blood toxicological analysis for alcohol, benzodiazepines, sedative-hypnotics, or other substances suggested the diagnosis of GHB withdrawal. Later analysis of a patient drug sample confirmed the presence of GHB. The patient required 507 mg of lorazepam and 120 mg of diazepam over 90 h to control agitation. This is one of the few reported cases of GHB withdrawal and one of the most severe. Given the increasing use of GHB, more cases of severe GHB withdrawal should be anticipated.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10645841     DOI: 10.1016/s0736-4679(99)00163-8

Source DB:  PubMed          Journal:  J Emerg Med        ISSN: 0736-4679            Impact factor:   1.484


  21 in total

1.  Some light from the heat: implications of rave parties for clinicians.

Authors:  M J Rieder
Journal:  CMAJ       Date:  2000-06-27       Impact factor: 8.262

2.  Gamma-hydroxybutyrate withdrawal syndrome: a case report.

Authors:  Michael A Kuiper; Nicole Peikert; E Christiaan Boerma
Journal:  Cases J       Date:  2009-03-25

3.  Chronic intragastric administration of gamma-butyrolactone produces physical dependence in baboons.

Authors:  Amy K Goodwin; Roland R Griffiths; P Rand Brown; Wolfgang Froestl; Cornelis Jakobs; K Michael Gibson; Elise M Weerts
Journal:  Psychopharmacology (Berl)       Date:  2006-09-20       Impact factor: 4.530

Review 4.  Pharmacological Treatment in γ-Hydroxybutyrate (GHB) and γ-Butyrolactone (GBL) Dependence: Detoxification and Relapse Prevention.

Authors:  Rama M Kamal; Martijn S van Noorden; Wim Wannet; Harmen Beurmanjer; Boukje A G Dijkstra; Arnt Schellekens
Journal:  CNS Drugs       Date:  2017-01       Impact factor: 5.749

Review 5.  gamma-Hydroxybutyrate/sodium oxybate: neurobiology, and impact on sleep and wakefulness.

Authors:  Daniel Pardi; Jed Black
Journal:  CNS Drugs       Date:  2006       Impact factor: 5.749

6.  Intravenous self-administration of γ-hydroxybutyrate (GHB) in baboons.

Authors:  Amy K Goodwin; Barbara J Kaminski; Roland R Griffiths; Nancy A Ator; Elise M Weerts
Journal:  Drug Alcohol Depend       Date:  2010-11-26       Impact factor: 4.492

7.  [Agitation and gamma-hydroxybutyrate].

Authors:  M Hardmeier; M Eichhorn; G Stoppe
Journal:  Nervenarzt       Date:  2006-09       Impact factor: 1.214

8.  Comparative abuse liability of GHB and ethanol in humans.

Authors:  Matthew W Johnson; Roland R Griffiths
Journal:  Exp Clin Psychopharmacol       Date:  2013-02-18       Impact factor: 3.157

Review 9.  Illicit gamma-hydroxybutyrate (GHB) and pharmaceutical sodium oxybate (Xyrem): differences in characteristics and misuse.

Authors:  Lawrence P Carter; Daniel Pardi; Jane Gorsline; Roland R Griffiths
Journal:  Drug Alcohol Depend       Date:  2009-06-02       Impact factor: 4.492

10.  GHB ameliorates naloxone-induced conditioned place aversion and physical aspects of morphine withdrawal in mice.

Authors:  Concepción Maldonado; Marta Rodríguez-Arias; María A Aguilar; José Miñarro
Journal:  Psychopharmacology (Berl)       Date:  2004-06-04       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.